Champix seems to have had little impact on rates of smoking cessation

According to research done in the USA varenicline (trading under the name Champix in the UK and Chantix in the USA) appears to have had no significant impact on the rates of smoking in the USA, and the effectiveness of this drug is short-lived compared to other cessation aides. Findings from this research have been published in the journal Tobacco Control.

More details at http://www.empr.com/news/varenicline-not-improving-quit-rates-smoking/article/433144/